Alpha-Difluoromethylornithine, a Polyamine Inhibitor: Its Potential Role in Controlling Hair Growth and in Cancer Treatment and Chemoprevention

A user shared impressive hair regrowth results after 4 months using topical minoxidil and dutasteride but is concerned about slow-growing baby hairs. Responses suggest patience, as full results can take up to 2 years.

Dutasteride at 0.5 mg/day does not significantly alter allopregnanolone levels, but higher doses (2.5 mg/day) do. Dutasteride may also have anti-neuroinflammatory effects, but the impact on neurosteroids is still debated.

Aspirin reduces the effectiveness of minoxidil for hair loss. Quercetin and 5-ASA medications also inhibit the necessary enzyme for minoxidil to work.

User discusses Alfatradiol (17a-Estradiol) as a potential hair loss treatment with mixed results. Concerns include low dosage, receptor theory, and possible increased aromatase activity on scalp.

NMN shows promise in promoting hair growth by reducing oxidative stress and weakening androgens. It may be a beneficial addition to hair loss treatments like Minoxidil and Finasteride.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.